The Logic Of Biologics - Is Regeneron The Next Roche?

Tim Gallagher shared with you: Interesting stats from this article showing the value of Biologics >small molecules "For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics"   The Logic Of Biologics - Is Regeneron The Next Roche? forbes.com For preclinical compounds, it takes an average of 44 small-molecule candidates to achieve one final approval versus nine biologic drug candidates In Phase II development, it takes an average of 11 small-molecule candidates to achieve one final approval versus four biologic drug candidates Only 19 percent of small-molecule compounds will advance from Phase II to Phase III studies, versus 44 percent for biologics Only 60 percent of small-molecule compounds will successfully complete Phase III studies versus 79 percent for biologics